Literature DB >> 23609047

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay.

Irène Baccelli1, Andreas Schneeweiss, Sabine Riethdorf, Albrecht Stenzinger, Anja Schillert, Vanessa Vogel, Corinna Klein, Massimo Saini, Tobias Bäuerle, Markus Wallwiener, Tim Holland-Letz, Thomas Höfner, Martin Sprick, Martina Scharpff, Frederik Marmé, Hans Peter Sinn, Klaus Pantel, Wilko Weichert, Andreas Trumpp.   

Abstract

It has been hypothesized that carcinoma metastasis is initiated by a subpopulation of circulating tumor cells (CTCs) found in the blood of patients. However, although the presence of CTCs is an indicator of poor prognosis in several carcinoma entities, the existence and phenotype of metastasis-initiating cells (MICs) among CTCs has not been experimentally demonstrated. Here we developed a xenograft assay and used it to show that primary human luminal breast cancer CTCs contain MICs that give rise to bone, lung and liver metastases in mice. These MIC-containing CTC populations expressed EPCAM, CD44, CD47 and MET. In a small cohort of patients with metastases, the number of EPCAM(+)CD44(+)CD47(+)MET(+) CTCs, but not of bulk EPCAM(+) CTCs, correlated with lower overall survival and increased number of metastasic sites. These data describe functional circulating MICs and associated markers, which may aid the design of better tools to diagnose and treat metastatic breast cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23609047     DOI: 10.1038/nbt.2576

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  43 in total

1.  Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models.

Authors:  Huiping Liu; Manishkumar R Patel; Jennifer A Prescher; Antonia Patsialou; Dalong Qian; Jiahui Lin; Susanna Wen; Ya-Fang Chang; Michael H Bachmann; Yohei Shimono; Piero Dalerba; Maddalena Adorno; Neethan Lobo; Janet Bueno; Frederick M Dirbas; Sumanta Goswami; George Somlo; John Condeelis; Christopher H Contag; Sanjiv Sam Gambhir; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

Review 3.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.

Authors:  Mark P Chao; Irving L Weissman; Ravindra Majeti
Journal:  Curr Opin Immunol       Date:  2012-02-04       Impact factor: 7.486

4.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

5.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

Review 6.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

7.  Tumor self-seeding by circulating cancer cells.

Authors:  Mi-Young Kim; Thordur Oskarsson; Swarnali Acharyya; Don X Nguyen; Xiang H-F Zhang; Larry Norton; Joan Massagué
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

8.  Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.

Authors:  Sabine Kasimir-Bauer; Oliver Hoffmann; Diethelm Wallwiener; Rainer Kimmig; Tanja Fehm
Journal:  Breast Cancer Res       Date:  2012-01-20       Impact factor: 6.466

9.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

Review 10.  The evolving concept of cancer and metastasis stem cells.

Authors:  Irène Baccelli; Andreas Trumpp
Journal:  J Cell Biol       Date:  2012-08-06       Impact factor: 10.539

View more
  408 in total

1.  Liquid biopsy: Potential and challenges.

Authors:  Klaus Pantel; Catherine Alix-Panabières
Journal:  Mol Oncol       Date:  2016-02-01       Impact factor: 6.603

Review 2.  Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells.

Authors:  Joshua M Jackson; Małgorzata A Witek; Joyce W Kamande; Steven A Soper
Journal:  Chem Soc Rev       Date:  2017-07-17       Impact factor: 54.564

Review 3.  Challenges in circulating tumour cell research.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2014-07-31       Impact factor: 60.716

Review 4.  Metastasis of circulating tumor cells: favorable soil or suitable biomechanics, or both?

Authors:  Ana Sofia Azevedo; Gautier Follain; Shankar Patthabhiraman; Sébastien Harlepp; Jacky G Goetz
Journal:  Cell Adh Migr       Date:  2015-08-27       Impact factor: 3.405

5.  Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device.

Authors:  Bee Luan Khoo; Gianluca Grenci; Ying Bena Lim; Soo Chin Lee; Jongyoon Han; Chwee Teck Lim
Journal:  Nat Protoc       Date:  2017-12-07       Impact factor: 13.491

6.  Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits.

Authors:  Xiaosai Yao; Atish D Choudhury; Yvonne J Yamanaka; Viktor A Adalsteinsson; Todd M Gierahn; Christina A Williamson; Carla R Lamb; Mary-Ellen Taplin; Mari Nakabayashi; Matthew S Chabot; Tiantian Li; Gwo-Shu M Lee; Jesse S Boehm; Philip W Kantoff; William C Hahn; K Dane Wittrup; J Christopher Love
Journal:  Integr Biol (Camb)       Date:  2014-02-13       Impact factor: 2.192

7.  Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).

Authors:  Michael L Pearl; Huan Dong; Shaun Tulley; Qiang Zhao; Marc Golightly; Stanley Zucker; Wen-Tien Chen
Journal:  Gynecol Oncol       Date:  2015-03-11       Impact factor: 5.482

Review 8.  Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.

Authors:  Daniel A Haber; Victor E Velculescu
Journal:  Cancer Discov       Date:  2014-05-06       Impact factor: 39.397

Review 9.  Biology and clinical significance of circulating tumor cell subpopulations in lung cancer.

Authors:  Linda O'Flaherty; Harriet Wikman; Klaus Pantel
Journal:  Transl Lung Cancer Res       Date:  2017-08

Review 10.  Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.

Authors:  Sumitra Mohan; Francesca Chemi; Ged Brady
Journal:  Transl Lung Cancer Res       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.